Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Virtual KOL Investor Event November 11, 2025 © 2025 Esperion Therapeutics, Inc. All rights reserved. Forward-looking Statements & Disclosures Breaking the Statin Intolerance Barrier: Closing the Care Gap in Cardiovascular Health This investor presentation contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding marketing strategy and commercialization plans, current and planned operational expenses, expected profi ...

Financial Performance - Total revenue reached $82.4 million, a 12% increase[7,40] - U S net product sales increased by 42% to $40.3 million[7,40] - Collaboration revenue was $42.1 million, a 7% decrease, but adjusting for a one-time settlement agreement milestone with DSE received in Q2 2024, it represents a 105% increase[40] - The company achieved its first quarter of operating income from ongoing business and anticipates sustainable profitability beginning in Q1 2026[4,40] - Cash and cash equivalents stand at $86.1 million[43] Marketing and Sales - Over 28,000 healthcare providers are now writing prescriptions for the company's products[9,20] - Retail prescription equivalents increased by 10% compared to Q1 2025[7,20,48] - The consumer statin intolerance website received over 650,000 visits in Q2, and the HCP statin intolerance site had over 600,000 click-throughs[15] - A balanced direct and digital marketing approach resulted in 23% of prescriptions written by physicians with only digital touchpoints and 38% of new writer prescriptions driven by digital-only touchpoints[17,20] Pipeline and Strategic Initiatives - The company is advancing IND-enabling studies for a new program in primary sclerosing cholangitis (PSC), representing an approximately $1 billion annual market opportunity, with potential first-in-human studies in 2H 2026[25,36] - Settlements were reached with three ANDA filers to protect NEXLETOL's IP until 2040[25]

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 grew 63% year over year to $65 million after adjusting for a one-time milestone received in Q1 2024 [7][19] - U.S. net product revenue increased 41% year over year to $34.9 million, driven by expanded label and commercial initiatives [7][19] - Collaboration revenue decreased approximately 73% to $30.1 million due to the settlement agreement milestone with DSE, but grew 97% excluding that milestone [21] Business Line Data and Key Metrics Changes - U.S. product sales growth was impacted by a flat lipid market and seasonal headwinds, with script growth increasing only 2% sequentially compared to Q4 2024 [7][20] - The market access team achieved significant milestones, including the removal of prior authorizations for over 30 plans, enhancing access for patients [8][10] - The company expanded its field reimbursement support team threefold to 15 specialists, improving support for prescribers [7][38] Market Data and Key Metrics Changes - The company reported that approximately 472,500 patients have been treated with its therapies in Europe, with royalty revenue from DSE increasing 8% from Q4 2024 to $10.5 million in Q1 2025 [13][14] - The Japanese market is expected to be a significant contributor, with approval for bempedoic acid anticipated in the second half of 2025 [14] Company Strategy and Development Direction - The company is focused on revenue growth, portfolio expansion, and pipeline advancement, with a commitment to improving cardiovascular health [5][23] - A new triple combination product is being developed, expected to provide significant LDL cholesterol reduction and is projected for commercialization in 2027 [12][62] - The company aims to leverage its leadership in ACLY biology and expand into high-need indications, such as primary sclerosing cholangitis (PSC) [16] Management's Comments on Operating Environment and Future Outlook - Management noted that the first quarter faced challenges due to changes in Medicare Part D and higher out-of-pocket costs, but early Q2 trends show prescription volume tracking approximately 8% higher than Q1 [20][58] - The management expressed confidence in the strategic initiatives to drive growth and improve patient access to innovative therapies [23][24] Other Important Information - The company reiterated its full-year 2025 operating expense guidance of approximately $215 million to $235 million, including $15 million in non-cash expenses related to stock compensation [22] - The company is actively pursuing new business development opportunities and is not waiting for specific milestones to execute deals [29] Q&A Session Summary Question: When should we expect a new business development deal? - Management is making good progress but will not set a timeline for a deal, as they want to ensure it makes sense for the company [29] Question: Is the triple combination a defensive strategy? - The triple combination is seen as a convenient option for patients, potentially being the most efficacious LDL-lowering drug on the market [31] Question: Is the sales force right-sized? - The current sales force of approximately 155 representatives is deemed appropriate, balancing personal and digital promotion [37] Question: How is the company addressing physician education on statin intolerance? - The company is focusing on educating physicians about statin intolerance, with significant traction in messaging about the unmet need for patients who cannot tolerate statins [40] Question: What is the gross margin trajectory? - Gross margin is influenced by the sales mix between U.S. and partner sales, with expectations for improvement as tech transfer progresses [65]